A phase II, randomized, multicenter study to assess the efficacy, safety, and tolerability of zibotentan (ZD4054) in combination with pemetrexed in patients with advanced non-small cell lung cancer

Cancer Chemotherapy and Pharmacology

Volumn 67, Issue 5, 2011, Pages 1203-1208

  Chouaid, Christos ^a   Nathan, Faith ^b   Pemberton, Kristine ^b   Morris, Thomas ^b  

^a HÔPITAL SAINT ANTOINE   (France)

^b ASTRAZENECA   (United Kingdom)

Author keywords

Cancer; Clinical trial; Endothelin; NSCLC; Zibotentan

Indexed keywords

PEMETREXED; PLACEBO; PLATINUM COMPLEX; TAXANE DERIVATIVE; ZIBOTENTAN;

ABDOMINAL PAIN; ADVANCED CANCER; ANEMIA; ARTICLE; BODY WEIGHT; BRAIN METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER RADIOTHERAPY; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FEBRILE BONE MARROW APLASIA; FEMALE; HUMAN; KIDNEY FAILURE; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PANCYTOPENIA; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; UNSPECIFIED SIDE EFFECT; UPPER GASTROINTESTINAL BLEEDING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DOUBLE-BLIND METHOD; GLUTAMATES; GUANINE; HUMANS; LUNG NEOPLASMS; NEOPLASM METASTASIS; PYRROLIDINES; SURVIVAL RATE;

EID: 79955565641     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-010-1538-z     Document Type: Article

References (17)

1. A Jemal R Siegel E Ward Y Hao J Xu MJ Thun 2009 Cancer statistics, 2009 CA Cancer J Clin 59 225 249 19474385 10.3322/caac.20006
2. V Hirsh 2010 Systemic therapies in metastatic non-small-cell lung cancer with emphasis on targeted therapies: the rational approach Curr Oncol 17 13 23 20404973 1:STN:280:DC%2BC3c3nsVKrsw%3D%3D
3. N Hanna FA Shepherd FV Fossella JR Pereira F De Marinis J von Pawel U Gatzemeier TC Tsao M Pless T Muller HL Lim C Desch K Szondy R Gervais Manegold C Shaharyar S Paul P Paoletti L Einhorn PA Bunn Jr 2004 Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy J Clin Oncol 22 1589 1597 15117980 10.1200/JCO.2004.08.163 1:CAS:528:DC%2BD2cXpsVWmurk%3D (Pubitemid 41079796)
4. FA Shepherd J Rodrigues Pereira T Ciuleanu EH Tan V Hirsh S Thongprasert D Campos S Maoleekoonpiroj M Smylie R Martins M van Kooten M Dediu B Findlay D Tu D Johnston A Bezjak G Clark P Santabarbara L Seymour 2005 Erlotinib in previously treated non-small-cell lung cancer N Engl J Med 353 123 132 16014882 10.1056/NEJMoa050753 1:CAS:528:DC%2BD2MXmtFaksbo%3D (Pubitemid 41058344)
5. ES Kim V Hirsh T Mok MA Socinski R Gervais YL Wu LY Li CL Watkins MV Sellers ES Lowe Y Sun ML Liao K Osterlind M Reck AA Armour FA Shepherd SM Lippman JY Douillard 2008 Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial Lancet 372 1809 1818 19027483 10.1016/S0140-6736(08)61758-4 1:CAS:528:DC%2BD1cXhsVWhtbjM
6. JY Douillard FA Shepherd V Hirsh T Mok MA Socinski R Gervais ML Liao H Bischoff M Reck MV Sellers CL Watkins G Speake AA Armour ES Kim 2010 Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial J Clin Oncol 28 744 752 20038723 10.1200/JCO.2009.24.3030 1:CAS:528: DC%2BC3cXksVyrsbY%3D
7. JA Katzel MP Fanucchi Z Li 2009 Recent advances of novel targeted therapy in non-small cell lung cancer J Hematol Oncol 2 2 19159467 10.1186/1756-8722-2- 2
8. JW Growcott 2009 Preclinical anticancer activity of the specific endothelin A receptor antagonist ZD4054 Anticancer Drugs 20 83 88 19065106 10.1097/CAD.0b013e328320791c 1:CAS:528:DC%2BD1MXhvVSitLs%3D
9. L Boldrini S Gisfredi S Ursino P Faviana M Lucchi F Melfi A Mussi F Basolo G Fontanini 2005 Expression of endothelin-1 is related to poor prognosis in non-small cell lung carcinoma Eur J Cancer 41 2828 2835 16298124 10.1016/j.ejca.2005.08.030 1:CAS:528:DC%2BD2MXht1OntLzM (Pubitemid 41713120)
10. LJ Knight J Burrage SR Bujac C Haggerty A Graham NJ Gibson G Ellison JW Growcott AN Brooks AM Hughes G Xinarianos G Nikolaidis JK Field T Liloglou 2009 Epigenetic silencing of the endothelin-B receptor gene in non-small cell lung cancer Int J Oncol 34 465 471 19148482 1:CAS:528:DC%2BD1MXisVGis7o%3D
11. ND James A Caty H Payne M Borre BA Zonnenberg P Beuzeboc S McIntosh T Morris D Phung NA Dawson 2010 Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan (ZD4054) in patients with metastatic castration-resistant prostate cancer and bone metastases who were pain-free or mildly symptomatic for pain: a double-blind, placebo-controlled, randomized Phase II trial BJU Int 106 966 973 20840318 10.1111/j.1464-410X.2010. 09638.x 1:CAS:528:DC%2BC3cXhsVSksrfL
12. K Fizazi K Miller 2009 Specific endothelin-A receptor antagonism for the treatment of advanced prostate cancer BJU Int 104 1423 1425 19624592 10.1111/j.1464-410X.2009.08740.x 1:CAS:528:DC%2BD1MXhsFaiur7O
13. LV Rubinstein EL Korn B Freidlin S Hunsberger SP Ivy MA Smith 2005 Design issues of randomized phase II trials and a proposal for phase II screening trials J Clin Oncol 23 7199 7206 16192604 10.1200/JCO.2005.01.149
14. World Medical Association (WMA) (1964) Declaration of Helsinki. Ethical principles for medical research involving human subjects. Adopted by the 18th WMA general assembly, Helsinki, Finland. June 1964. Available at http://www.wma.net/en/30publications/10policies/b3/index.html
15. P Therasse SG Arbuck EA Eisenhauer J Wanders RS Kaplan L Rubinstein J Verweij M Van Glabbeke AT van Oosterom MC Christian SG Gwyther 2000 New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 205 216 10655437 10.1093/jnci/92.3.205 1:STN:280:DC%2BD3c7it1Gitg%3D%3D
16. MA Carducci F Saad PA Abrahamsson DP Dearnaley CC Schulman SA North DJ Sleep JD Isaacson JB Nelson 2007 A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer Cancer 110 1959 1966 17886253 10.1002/cncr.22996 1:CAS:528:DC%2BD2sXhtlertbrP (Pubitemid 350036854)
17. Russo F, Bearz A, Pampaloni G (2008) Pemetrexed single agent chemotherapy in previously treated patients with locally advanced or metastatic non-small cell lung cancer. BMC Cancer 8:216-223